Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.

Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, Kerbel RS. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia. 2011 Jan; 13(1):40-8.

View in: PubMed

subject areas

Animals
Cell Proliferation
Cyclophosphamide
Drug Resistance, Neoplasm
Humans
Male
Maximum Tolerated Dose
Mice
Neoplasm Transplantation
Tumor Burden
Tumor Cells, Cultured

authors with profiles

Giulio Francia

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support